- Home
- ZGN vs KROS Comparison
ZGN vs KROS Comparison
Compare ZGN & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZGN
- KROS
- Stock Information
- Founded
- ZGN 1910
- KROS 2015
- Country
- ZGN Italy
- KROS United States
- Employees
- ZGN N/A
- KROS N/A
- Industry
- ZGN Apparel
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ZGN Consumer Discretionary
- KROS Health Care
- Exchange
- ZGN Nasdaq
- KROS Nasdaq
- Market Cap
- ZGN 2.2B
- KROS 633.5M
- IPO Year
- ZGN N/A
- KROS 2020
- Fundamental
- Price
- ZGN $8.02
- KROS $15.92
- Analyst Decision
- ZGN Buy
- KROS Buy
- Analyst Count
- ZGN 2
- KROS 11
- Target Price
- ZGN $12.95
- KROS $68.83
- AVG Volume (30 Days)
- ZGN 670.1K
- KROS 1.9M
- Earning Date
- ZGN 09-18-2024
- KROS 02-26-2025
- Dividend Yield
- ZGN 1.63%
- KROS N/A
- EPS Growth
- ZGN 14.68
- KROS N/A
- EPS
- ZGN 0.42
- KROS N/A
- Revenue
- ZGN $2,101,802,207.00
- KROS $651,000.00
- Revenue This Year
- ZGN $1.34
- KROS $224.66
- Revenue Next Year
- ZGN $3.73
- KROS N/A
- P/E Ratio
- ZGN $19.79
- KROS N/A
- Revenue Growth
- ZGN 17.68
- KROS 8037.50
- 52 Week Low
- ZGN $7.13
- KROS $15.33
- 52 Week High
- ZGN $15.26
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- ZGN 42.99
- KROS 22.66
- Support Level
- ZGN $8.12
- KROS $15.33
- Resistance Level
- ZGN $8.87
- KROS $17.25
- Average True Range (ATR)
- ZGN 0.31
- KROS 1.37
- MACD
- ZGN -0.07
- KROS -0.48
- Stochastic Oscillator
- ZGN 6.70
- KROS 10.31
About ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. It operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment; and the Tom Ford Fashion segment. It generates the majority of its revenue from the Zegna segment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.